Overview

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Status:
Terminated
Trial end date:
2003-10-27
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S